Innoviva (INVA) Revenue Growth (1y) (2012 - 2026)
Innoviva (INVA) Revenue Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 64.03% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 10.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.56% |
| Dec 31, 2025 | -12.15% |
| Sep 30, 2025 | 11.17% |
| Jun 30, 2025 | 0.39% |
| Mar 31, 2025 | 3,453.81% |
| Dec 31, 2024 | -19.18% |
| Sep 30, 2024 | 18.82% |
| Jun 30, 2024 | 3,433.71% |
| Mar 31, 2024 | 35.03% |
| Dec 31, 2023 | 45.39% |
| Sep 30, 2023 | -15.41% |
| Jun 30, 2023 | -31.18% |
| Mar 31, 2023 | -16.99% |
| Dec 31, 2022 | 6.27% |
| Sep 30, 2022 | -6.56% |
| Jun 30, 2022 | 50.04% |
| Mar 31, 2022 | 41.72% |
| Dec 31, 2021 | 96.23% |
| Sep 30, 2021 | 220.41% |
| Jun 30, 2021 | -96.53% |